IR@PKUHSC  > 北京大学第三临床医学院  > 呼吸科
学科主题临床医学
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China
Zhang, Ying-yuan1; Huang, Hai-hui1; Ren, Zhen-yi2; Zheng, Hong-guang3; Yu, Yun-song4; Lue, Xiao-ju5; Xiao, Zu-ke6; Yang, Hui-fen7; Xiu, Qing-yu8; Chen, Bao-yuan9; Yue, Hong-mei10; Hao, Qing-lin11; Huang, Jian-an12; Ma, Hui13; Xiao, Wei14; Guo, Dong-yang15; Si, Bin16; Sun, Sheng-hua17; Zhang, Wei18; Li, Qi-hao19; Shen, Hua-hao20; Duan, Jian21; Li, Hua-yin22; Yao, Wan-zhen23; Gu, Jun-ming24; Xia, Qian-ming25; Ying, Ke-jing26; Liu, Ao27; Yang, He-ping28; Shi, Min-hua29; Sun, Tie-ying30; Ding, Guo-hua31; Wu, Guo-ming32
关键词Lower respiratory tract infection Urinary tract infection Levofloxacin Clinical study
刊名JOURNAL OF INFECTION AND CHEMOTHERAPY
2009-10-01
DOI10.1007/s10156-009-0713-9
15期:5页:301-311
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Infectious Diseases ; Pharmacology & Pharmacy
研究领域[WOS]Infectious Diseases ; Pharmacology & Pharmacy
关键词[WOS]STREPTOCOCCUS-PNEUMONIAE ; ANTIMICROBIAL RESISTANCE ; PHARMACODYNAMICS ; PHARMACOKINETICS ; FLUOROQUINOLONES ; CIPROFLOXACIN ; SURVEILLANCE ; AGENTS ; MODEL
英文摘要

Levofloxacin (LVFX), a fluoroquinolone agent, has a broad spectrum that covers Gram-positive and -negative bacteria and atypical pathogens. It demonstrates good clinical efficacy in the treatment of various infections, including lower respiratory tract infections (LRTIs) and urinary tract infections (UTIs). To evaluate the efficacy and safety of oral LVFX 500 mg once daily, a large open-label clinical trial was conducted in 1266 patients (899 with LRTIs and 367 with UTIs) at 32 centers in China. In the per-protocol population, the clinical efficacy rate (cure or improvement) at 7 to 14 days after the end of treatment was 96.4% (666/691) for LRTIs and 95.7% (267/279) for UTIs. In 53 patients diagnosed with atypical pneumonia the treatment was effective. The bacteriological efficacy rate was 96.6% (256/265) for LRTIs and 93.3% (126/135) for UTIs. The eradication rate of the causative pathogens was 100% (33/33) for Haemophilus influenzae and 96.0% (24/25) for Streptococcus pneumoniae in LRTIs, and 94.1% (80/85) for Escherichia coli in UTIs. The overall efficacy rates were 89.3% (617/691) for LRTIs and 87.8% (245/279) for UTIs. The incidence of drug-related adverse events (ADRs) was 17.3% (215/1245), and the incidence of drug-related laboratory abnormalities was 15.7% (191/1213). Common ADRs were dizziness, nausea, and insomnia. Common laboratory abnormalities included "WBC decreased", "alanine aminotransferase (ALT) increased", "aspartate aminotransferase (AST) increased", and "lactate dehydrogenase (LDH) increased". All of these events were mentioned in the package inserts of fluoroquinolones including LVFX, and most events were mild and transient. Thirty-four patients (2.7%) were withdrawn from the study because of the ADRs. No new ADRs were found. This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs.

语种英语
WOS记录号WOS:000271106500006
资助机构Daiichi Pharmaceutical Co., Ltd, Beijing, China
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/68164
专题北京大学第三临床医学院_呼吸科
北京大学第三临床医学院_运动医学研究所
作者单位1.Mil Gen Hosp Shenyang, Dept Nephrol, Shenyang, Peoples R China
2.Peoples Hosp Jiangxi Prov, Dept Resp Med, Nanchang, Peoples R China
3.Fudan Univ, Inst Antibiot, Huashan Hosp, Shanghai 200040, Peoples R China
4.First Peoples Hosp Hangzhou, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China
5.Zhejiang Univ, Dept Infect Dis, Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
6.Sichuan Univ, Dept Infect Dis, Huaxi Hosp, Chengdu 610064, Peoples R China
7.Tianjin Med Univ, Hosp 2, Dept Infect Dis, Tianjin, Peoples R China
8.Shanghai Changzheng Hosp, Dept Resp Med, Shanghai, Peoples R China
9.Tianjin Med Univ, Dept Resp Med, Gen Hosp, Tianjin, Peoples R China
10.Lanzhou Univ, Hosp 1, Dept Resp Med, Lanzhou 730000, Peoples R China
11.Kunming Med Univ, Dept Resp Med, Hosp 1, Kunming, Peoples R China
12.Suzhou Univ, Hosp 1, Dept Resp Med, Suzhou 215006, Peoples R China
13.Peoples Hosp Gansu Prov, Dept Resp Med, Lanzhou, Peoples R China
14.Shangdong Univ, Dept Resp Med, Qilu Hosp, Jinan, Peoples R China
15.Mil Gen Hosp Chengdu, Dept Nephrol, Chengdu, Peoples R China
16.Mil Gen Hosp Wuhan, Dept Resp Med, Wuhan, Peoples R China
17.Zhongnan Univ, Xiangya Hosp 3, Dept Resp Med, Changsha, Hunan, Peoples R China
18.Nanchang Univ, Hosp 1, Dept Resp Med, Nanchang, Peoples R China
19.Kunming Med Univ, Hosp 2, Dept Resp Med, Kunming, Peoples R China
20.Zhejiang Univ, Dept Resp Med, Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China
21.Mil Gen Hosp Kunming, Dept Nephrol, Kunming, Peoples R China
22.Fudan Univ, Zhongshan Hosp, Dept Resp Med, Shanghai 200040, Peoples R China
23.Peking Univ, Dept Resp Med, Hosp 3, Beijing 100871, Peoples R China
24.Dalian Med Univ, Hosp 2, Dept Resp Med, Dalian, Peoples R China
25.Mil Gen Hosp Chengdu, Dept Resp Med, Chengdu, Peoples R China
26.Mil Gen Hosp Kunming, Dept Resp Med, Kunming, Peoples R China
27.Beijing Hosp, Dept Resp Med, Beijing, Peoples R China
28.Zhejiang Univ, Dept Resp Med, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China
29.Third Mil Med Univ, Hosp 1, Dept Resp Med, Chongqing, Peoples R China
30.Suzhou Univ, Hosp 2, Dept Resp Med, Suzhou 215006, Peoples R China
31.Wuhan Univ, Dept Nephrol, Peoples Hosp, Wuhan 430072, Peoples R China
32.Third Mil Med Univ, Hosp 2, Dept Resp Med, Chongqing, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Ying-yuan,Huang, Hai-hui,Ren, Zhen-yi,et al. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China[J]. JOURNAL OF INFECTION AND CHEMOTHERAPY,2009,15(5):301-311.
APA Zhang, Ying-yuan.,Huang, Hai-hui.,Ren, Zhen-yi.,Zheng, Hong-guang.,Yu, Yun-song.,...&Wu, Guo-ming.(2009).Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.JOURNAL OF INFECTION AND CHEMOTHERAPY,15(5),301-311.
MLA Zhang, Ying-yuan,et al."Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China".JOURNAL OF INFECTION AND CHEMOTHERAPY 15.5(2009):301-311.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Ying-yuan]的文章
[Huang, Hai-hui]的文章
[Ren, Zhen-yi]的文章
百度学术
百度学术中相似的文章
[Zhang, Ying-yuan]的文章
[Huang, Hai-hui]的文章
[Ren, Zhen-yi]的文章
必应学术
必应学术中相似的文章
[Zhang, Ying-yuan]的文章
[Huang, Hai-hui]的文章
[Ren, Zhen-yi]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。